The record
| Class | gh secretagogue |
|---|---|
| Also known as | Examorelin, Hexarelin acetate (common salt form), His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2 |
| Chain length | - |
| Molecular weight | 887.03 Da |
| Half-life | ≈120 minutes (reported human PK after IV administration). |
| Route | IV and SC reported in human PK/PD work. |
| Studied for | Not approved as a routine therapeutic; studied in humans for endocrine/cardiometabolic research. |
| Research use | GH-axis stimulation models; cardiac/endocrine research; GHSR pharmacology. |
| What has been shown | Robust, acute GH secretagogue activity in human studies. |
| How it works | Potent ghrelin receptor (GHSR-1a) agonist → stimulates GH release (and can affect ACTH/cortisol and prolactin depending on protocol). |
| Patent status | - |
| Regulatory status | Not approved as a routine therapeutic; studied in humans for endocrine/cardiometabolic research. |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Muscle Hypertrophy / Anabolic Signaling (affection, 56%)
- GH Pulsatility Environment (affection, 85%)
- Adult GH deficiency (illness, 60%)
- Anti-aging protocols (illness, 40%)
- Anti-aging therapy (illness, 60%)
- Body composition optimization (illness, 48%)
- Cognitive support (illness, 30%)
- Duchenne muscular dystrophy (illness, 30%)
- Growth hormone deficiency (illness, 40%)
- HIV-associated lipodystrophy (illness, 30%)
- Metabolic syndrome (illness, 40%)
- Neuromuscular diseases (illness, 30%)
- Pediatric growth hormone deficiency (illness, 60%)
- Visceral adiposity reduction (illness, 30%)
- Muscle loss or weakness (symptom, 67%)